Reported Thursday, HUTCHMED Confirms ORPATHYS (Savolitinib) Retains Spot On China's National Reimbursement Drug List
Reported Thursday, HUTCHMED Confirms ORPATHYS (Savolitinib) Retains Spot On China's National Reimbursement Drug List
据报道，华大基因确认ORPATHYS（沙沃替尼）在中国国家医保药品目录中保留了其地位
ORPATHYS is an oral, potent, and highly selective MET tyrosine kinase inhibitor ("TKI"). It received conditional approval in China in June 2021 for the treatment of certain patients with non-small cell lung cancer ("NSCLC") with MET exon 14 skipping alterations. More than a third of the world's lung cancer patients are in China and, among those with NSCLC globally, approximately 2-3% have tumors with MET exon 14 skipping alterations.
ORPATHYS是一种口服的、有效的且高度选择性的MEt酪氨酸激酶抑制剂（"TKI"）。它于2021年6月在中国获得有条件批准，用于治疗某些患有MEt外显子14跳跃变异的非小细胞肺癌（"NSCLC"）患者。全球有超过三分之一的肺癌患者在中国，而在全球的NSCLC患者中，约有2-3%存在MEt外显子14跳跃变异的肿瘤。
资讯热榜
更新时间